Understanding the interplay between host immunity and Epstein-Barr virus in NPC patients

Emerging Microbes and Infections

Volumn 4, Issue 3, 2015, Pages

  Shen, Yong ^a,b   Zhang, Suzhan ^a,b   Sun, Ren ^a,b,c   Wu, Tingting ^a,b,c   Qian, Jing ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adaptive immunity; EBV; Immune evasion; Innate immunity; NPC

Indexed keywords

ANTIBODY; CYTOKINE; VIRUS ANTIGEN;

ADAPTIVE IMMUNITY; ANTIBODY DETECTION; ANTIGEN EXPRESSION; APOPTOSIS; CANCER PATIENT; CELL MATURATION; CELLULAR IMMUNITY; CLONAL ANERGY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HLA SYSTEM; HOST; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; NASOPHARYNX CARCINOMA; PHAGOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; COMPLICATION; IMMUNOLOGY; NASOPHARYNX TUMOR; PHYSIOLOGY; VIROLOGY; VIRUS LATENCY;

ADAPTIVE IMMUNITY; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY, INNATE; NASOPHARYNGEAL NEOPLASMS; VIRUS LATENCY;

EID: 84979500468     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2015.20     Document Type: Review

References (172)

1. Young LS, Dawson CW, Clark D et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988; 69 (Pt 5): 1051-1065.
2. Brooks L, Yao QY, Rickinson AB et al. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: Coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992; 66: 2689-2697.
3. Sam CK, Brooks LA, Niedobitek G et al. Analysis of Epstein-Barr virus infection in nasopharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma. Int J Cancer 1993; 53: 957-962.
4. Gilligan KJ, Rajadurai P, Lin JC et al. Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: Evidence for a viral protein expressed in vivo. J Virol 1991; 65: 6252-6259.
5. Decaussin G, Sbih-Lammali F, de Turenne-TessierMet al. Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res 2000; 60: 5584-5588.
6. Seto E, Yang L, Middeldorp J et al. Epstein-Barr virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-Associated gastric carcinoma tissues in the absence of lytic gene expression. J Med Virol 2005; 76: 82-88.
7. Old LJ, Boyse EA, Oettgen HF et al. Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells. Proc Natl Acad Sci USA 1966; 56: 1699-1704.
8. Henle W, Henle G, Ho HC et al. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst 1970; 44: 225-231.
9. Henle G, HenleW. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976; 17: 1-7.
10. Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986; 47: 883-889.
11. Lin JC, Wang WY, Chen KY et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350: 2461-2470.
12. Lo YM, Chan LY, Chan AT et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999; 59: 5452-5455.
13. Chan AT, Lo YM, Zee B et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94: 1614-1619.
14. Leung SF, Chan AT, Zee B et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 2003; 98: 288-291.
15. Wang WY, Twu CW, Chen HH et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 2010; 16: 1016-1024.
16. An X, Wang FH, Ding PR et al. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer 2011; 117: 3750-3757.
17. Wang WY, Twu CW, LinWY et al. Plasma Epstein-Barr virus DNA screening followed by (1)(8)F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma. Cancer 2011; 117: 4452-4459.
18. Desgranges C, de-The G, Wolf H et al. Further studies on the detection of the Epstein-Barr virusDNAin nasopharyngeal carcinoma biopsies from different parts of the world. IARC Sci Publ 1975; 11 (Pt 2): 191-193.
19. Cosmopoulos K, Pegtel M, Hawkins J et al. Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol 2009; 83: 2357-2367.
20. Wong AM, Kong KL, Tsang JW et al. Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer 2012; 118: 698-710.
21. Zhang G, Zong J, Lin S et al. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment. Int J Cancer 2015; 136: E301-E312.
22. Sivachandran N, Thawe NN, Frappier L. Epstein-Barr virus nuclear antigen 1 replication and segregation functions in nasopharyngeal carcinoma cell lines. J Virol 2011; 85: 10425-10430.
23. Mansouri S, Pan Q, Blencowe BJ et al. Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer. J Virol 2014; 88: 11166-11177.
24. Sheu LF, Chen A, Meng CL et al. Enhanced malignant progression of nasopharyngeal carcinoma cells mediated by the expression of Epstein-Barr nuclear antigen 1 in vivo. J Pathol 1996; 180: 243-248.
25. O'Neil JD, Owen TJ, Wood VH et al. Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. J Gen Virol 2008; 89: 2833-2842.
26. Sivachandran N, Sarkari F, Frappier L. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies. PLoS Pathog 2008; 4: E1000170.
27. Valentine R, Dawson CW, Hu C et al. Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-kappaB pathway in carcinoma cells by inhibiting IKK phosphorylation. Mol Cancer 2010; 9: 1.
28. Cao JY, Mansouri S, Frappier L. Changes in the nasopharyngeal carcinoma nuclear proteome induced by the EBNA1 protein of Epstein-Barr virus reveal potential roles for EBNA1 in metastasis and oxidative stress responses. J Virol 2012; 86: 382-394.
29. Wang L, Tian WD, Xu X et al. Epstein-Barr virus nuclear antigen 1 (EBNA1) protein induction of epithelial-mesenchymal transition in nasopharyngeal carcinoma cells. Cancer 2014; 120: 363-372.
30. Li B, Huang G, Zhang X et al. Increased phosphorylation of histone H3 at serine 10 is involved in Epstein-Barr virus latent membrane protein-1-induced carcinogenesis of nasopharyngeal carcinoma. BMC Cancer 2013; 13: 124.
31. Lo AK, Lo KW, Ko CW et al. Inhibition of the LKB1-AMPK pathway by the Epstein-Barr virus-encoded LMP1 promotes proliferation and transformation of human nasopharyngeal epithelial cells. J Pathol 2013; 230: 336-346.
32. Yu PH, Chou SF, Chen CL et al. Upregulation of endocan by Epstein-Barr virus latent membrane protein 1 and its clinical significance in nasopharyngeal carcinoma. PLoS One 2013; 8: E82254.
33. Kondo S, Seo SY, Yoshizaki T et al. EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells. Cancer Res 2006; 66: 9870-9877.
34. Aga M, Bentz GL, Raffa S et al. Exosomal HIF1alpha supports invasive potential of nasopharyngeal carcinoma-Associated LMP1-positive exosomes. Oncogene 2014; 33: 4613-4622.
35. Pathmanathan R, Prasad U, Sadler R et al. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995; 333: 693-698.
36. Dawson CW, Tramountanis G, Eliopoulos AG et al. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J Biol Chem 2003; 278: 3694-3704.
37. Liu HP, Chen CC, Wu CC et al. Epstein-Barr virus-encoded LMP1 interacts with FGD4 to activate Cdc42 and thereby promote migration of nasopharyngeal carcinoma cells. PLoS Pathog 2012; 8: E1002690.
38. Chen CC, Liu HP, Chao M et al. NF-kappaB-mediated transcriptional upregulation of TNFAIP2 by the Epstein-Barr virus oncoprotein, LMP1, promotes cell motility in nasopharyngeal carcinoma. Oncogene 2014; 33: 3648-3659.
39. Tsai CN, Tsai CL, Tse KP et al. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci USA 2002; 99: 10084-10089.
40. Yoshizaki T, Sato H, FurukawaMet al. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci USA 1998; 95: 3621-3626.
41. Horikawa T, Yoshizaki T, Sheen TS et al. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 2000; 89: 715-723.
42. Lee DC, Chua DT, Wei WI et al. Induction of matrix metalloproteinases by Epstein-Barr virus latent membrane protein 1 isolated from nasopharyngeal carcinoma. Biomed Pharmacother 2007; 61: 520-526.
43. Deng W, Pang PS, Tsang CM et al. Epstein-Barr virus-encoded latent membrane protein 1 impairs G2 checkpoint in human nasopharyngeal epithelial cells through defective Chk1 activation. PLoS One 2012; 7: E39095.
44. Guo L, Tang M, Yang L et al. Epstein-Barr virus oncoprotein LMP1 mediates survivin upregulation by p53 contributing to G1/S cell cycle progression in nasopharyngeal carcinoma. Int J Mol Med 2012; 29: 574-580.
45. Xu Y, Shi Y, Yuan Q et al. Epstein-Barr Virus encoded LMP1 regulates cyclin D1 promoter activity by nuclear EGFR and STAT3 in CNE1 cells. J Exp Clin Cancer Res 2013; 32: 90.
46. Kondo S, Wakisaka N, MuramatsuMet al. Epstein-Barr virus latent membrane protein 1 induces cancer stem/progenitor-like cells in nasopharyngeal epithelial cell lines. J Virol 2011; 85: 11255-11264.
47. Port RJ, Pinheiro-Maia S, Hu C et al. Epstein-Barr virus induction of the Hedgehog signalling pathway imposes a stem cell phenotype on human epithelial cells. J Pathol 2013; 231: 367-377.
48. Busson P, McCoy R, Sadler R et al. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J Virol 1992; 66: 3257-3262.
49. Heussinger N, Buttner M, Ott G et al. Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-Associated nasopharyngeal carcinoma. J Pathol 2004; 203: 696-699.
50. Rovedo M, Longnecker R. Epstein-barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity. J Virol 2007; 81: 84-94.
51. Kong QL, Hu LJ, Cao JY et al. Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog 2010; 6: E1000940.
52. Lan YY, Hsiao JR, Chang KC et al. Epstein-Barr virus latent membrane protein 2A promotes invasion of nasopharyngeal carcinoma cells through ERK/Fra-1-mediated induction of matrix metalloproteinase 9. J Virol 2012; 86: 6656-6667.
53. Allen MD, Young LS, Dawson CW. The Epstein-Barr virus-encodedLMP2AandLMP2B proteins promote epithelial cell spreading and motility. J Virol 2005; 79: 1789-1802.
54. Iwakiri D, Sheen TS, Chen JY et al. Epstein-Barr virus-encoded small RNA induces insulin-like growth factor 1 and supports growth of nasopharyngeal carcinoma-derived cell lines. Oncogene 2005; 24: 1767-1773.
55. Wong HL, Wang X, Chang RC et al. Stable expression of EBERs in immortalized nasopharyngeal epithelial cells confers resistance to apoptotic stress. Mol Carcinog 2005; 44: 92-101.
56. Seto E, Ooka T, Middeldorp J et al. Reconstitution of nasopharyngeal carcinoma-Type EBV infection induces tumorigenicity. Cancer Res 2008; 68: 1030-1036.
57. Ye Y, Zhou Y, Zhang L et al. EBV-miR-BART1 is involved in regulating metabolismassociated genes in nasopharyngeal carcinoma. Biochem Biophys Res Commun 2013; 436: 19-24.
58. Lei T, Yuen KS, Xu R et al. Targeting of DICE1 tumor suppressor by Epstein-Barr virusencoded miR-BART3 microRNA in nasopharyngeal carcinoma. Int J Cancer 2013; 133: 79-87.
59. Lo AK, To KF, Lo KW et al. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci USA 2007; 104: 16164-16169.
60. Choy EY, Siu KL, Kok KH et al. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med 2008; 205: 2551-2560.
61. Chan JY, Gao W, Ho WK et al. Overexpression of Epstein-Barr virus-encoded microRNA-BART7 in undifferentiated nasopharyngeal carcinoma. Anticancer Res 2012; 32: 3201-3210.
62. Cai LM, Lyu XM, LuoWRet al. EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN. Oncogene 27 October 2014. doi 10.1038/onc.2014.341.
63. Hsu CY, Yi YH, ChangKP et al. The Epstein-Barr virus-encoded microRNA MiR-BART9 promotes tumor metastasis by targeting E-cadherin in nasopharyngeal carcinoma. PLoS Pathog 2014; 10: E1003974.
64. Xie YJ, Long ZF, He XS. Involvement of EBV-encoded BART-miRNAs and dysregulated cellular miRNAs in nasopharyngeal carcinoma genesis. Asian Pac J Cancer Prev 2013; 14: 5637-5644.
65. Chen LC, Wang LJ, Tsang NM et al. Tumour inflammasome-derived IL-1beta recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. EMBO Mol Med 2012; 4: 1276-1293.
66. Ferradini L, Miescher S, Stoeck M et al. Cytotoxic potential despite impaired activation pathways in T lymphocytes infiltrating nasopharyngeal carcinoma. Int J Cancer 1991; 47: 362-370.
67. Hu H, Tang KF, Chua YN et al. Expression of interleukin-18 by nasopharyngeal carcinoma cells: A factor that possibly initiates the massive leukocyte infiltration. Hum Pathol 2004; 35: 722-728.
68. Giannini A, Bianchi S, Messerini L et al. Prognostic significance of accessory cells and lymphocytes in nasopharyngeal carcinoma. Pathol Res Pract 1991; 187: 496-502.
69. Zong YS, Zhang CQ, Zhang F et al. Infiltrating lymphocytes and accessory cells in nasopharyngeal carcinoma. Jpn J Cancer Res 1993; 84: 900-905.
70. Tang KF, Tan SY, Chan SH et al. A distinct expression of CC chemokines by macrophages in nasopharyngeal carcinoma: Implication for the intense tumor infiltration by T lymphocytes and macrophages. Hum Pathol 2001; 32: 42-49.
71. Beaulieu AD, Paquin R, Gosselin J. Epstein-Barr virus modulates de novo protein synthesis in human neutrophils. Blood 1995; 86: 2789-2798.
72. McColl SR, Roberge CJ, Larochelle B et al. EBV induces the production and release of IL-8 and macrophage inflammatory protein-1 alpha in human neutrophils. J Immunol 1997; 159: 6164-6168.
73. Fiola S, Gosselin D, Takada K et al. TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells. J Immunol 2010; 185: 3620-3631.
74. Iwakiri D, Zhou L, Samanta M et al. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med 2009; 206: 2091-2099.
75. Granucci F, Zanoni I, Pavelka N et al. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J Exp Med 2004; 200: 287-295.
76. Isobe Y, Sugimoto K, Yang L et al. Epstein-Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells. Cancer Res 2004; 64: 2167-2174.
77. Gaudreault E, Fiola S, Olivier M et al. Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. J Virol 2007; 81: 8016-8024.
78. Ariza ME, Glaser R, Kaumaya PT et al. The EBV-encoded dUTPase activates NF-kappa Bthrough the TLR2 and MyD88-dependent signaling pathway. J Immunol 2009; 182: 851-859.
79. Glaser R, Litsky ML, Padgett DA et al. EBV-encoded dUTPase induces immune dysregulation: Implications for the pathophysiology of EBV-Associated disease. Virology 2006; 346: 205-218.
80. Gosselin J, Flamand L, D9Addario M et al. Infection of peripheral blood mononuclear cells by herpes simplex and Epstein-Barr viruses. Differential induction of interleukin 6 and tumor necrosis factor-Alpha. J Clin Invest 1992; 89: 1849-1856.
81. Martel-RenoirD, Grunewald V, Touitou R et al. Qualitative analysis of the expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies. J Gen Virol 1995; 76 (Pt 6): 1401-1408.
82. Feng P, Ren EC, Liu D et al. Expression of Epstein-Barr virus lytic gene BRLF1 in nasopharyngeal carcinoma: Potential use in diagnosis. J Gen Virol 2000; 81: 2417-2423.
83. Ning S. Innate immune modulation in EBV infection. Herpesviridae 2011; 2: 1.
84. Larochelle B, Flamand L, Gourde P et al. Epstein-Barr virus infects and induces apoptosis in human neutrophils. Blood 1998; 92: 291-299.
85. Savard M, Belanger C, Tardif M et al. Infection of primary human monocytes by Epstein-Barr virus. J Virol 2000; 74: 2612-2619.
86. Tardif M, Savard M, Flamand L et al. Impaired protein kinase C activation/ translocation in Epstein-Barr virus-infected monocytes. J Biol Chem 2002; 277: 24148-24154.
87. Li L, Liu D, Hutt-Fletcher L et al. Epstein-Barr virus inhibits the development of dendritic cells by promoting apoptosis of their monocyte precursors in the presence of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood 2002; 99: 3725-3734.
88. Severa M, Giacomini E, Gafa V et al. EBV stimulates TLR-And autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: Implications for viral immune escape. Eur J Immunol 2013; 43: 147-158.
89. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Trends Microbiol 2000; 8: 410-418.
90. Randall RE, Goodbourn S. Interferons and viruses: An interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008; 89: 1-47.
91. Roberge CJ, Larochelle B, Rola-Pleszczynski M et al. Epstein-Barr virus induces GMCSF synthesis by monocytes: Effect on EBV-induced IL-1 and IL-1 receptor antagonist production in neutrophils. Virology 1997; 238: 344-352.
92. Roberge CJ, Poubelle PE, Beaulieu AD et al. The IL-1 and IL-1 receptor antagonist (IL-1Ra) response of human neutrophils to EBV stimulation. Preponderance of IL-Ra detection. J Immunol 1996; 156: 4884-4891.
93. Hannum CH, Wilcox CJ, Arend WP et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336-340.
94. Savard M, Belanger C, Tremblay MJ et al. EBV suppresses prostaglandin E2 biosynthesis in human monocytes. J Immunol 2000; 164: 6467-6473.
95. Gosselin J, Menezes J, D'Addario M et al. Inhibition of tumor necrosis factor-Alpha transcription by Epstein-Barr virus. Eur J Immunol 1991; 21: 203-208.
96. D'Addario M, Ahmad A, Morgan A et al. Binding of the Epstein-Barr virus major envelope glycoprotein gp350 results in the upregulation of the TNF-Alpha gene expression in monocytic cells via NF-kappaB involving PKC, PI3-K and tyrosine kinases. J Mol Biol 2000; 298: 765-778.
97. Fachiroh J, Stevens SJ, Haryana SM et al. Combination of Epstein-Barr virus scaffold (BdRF1/VCA-p40) and small capsid protein (BFRF3/VCA-p18) into a single molecule for improved serodiagnosis of acute and malignant EBV-driven disease. J Virol Methods 2010; 169: 79-86.
98. Thorley-Lawson DA, Poodry CA. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol 1982; 43: 730-736.
99. Gu AD, Xie YB, Mo HY et al. Antibodies against Epstein-Barr virus gp78 antigen: A novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology. J Gen Virol 2008; 89: 1152-1158.
100. Joab I, Nicolas JC, SchwaabGet al. Detection of anti-Epstein-Barr-virus transactivator (ZEBRA) antibodies in sera from patientswith nasopharyngeal carcinoma. Int J Cancer 1991; 48: 647-649.
101. Chien YC, Chen JY, Liu MY et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men.NEngl J Med 2001; 345: 1877-1882.
102. Paramita DK, Fatmawati C, Juwana H et al. Humoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls. J Med Virol 2011; 83: 665-678.
103. de Turenne-Tessier M, Jolicoeur P, Middeldorp JMet al. Expression and analysis of the Epstein-Barr virus BARF1-encoded protein from a tetracycline-regulatable adenovirus system. Virus Res 2005; 109: 9-18.
104. Paramita DK, Fachiroh J, Artama WT et al. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma. J Med Virol 2007; 79: 1710-1721.
105. Imai S, Nishikawa J, Takada K. Cell-To-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol 1998; 72: 4371-4378.
106. Shannon-Lowe CD, NeuhierlB, BaldwinGet al. Resting Bcells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells. Proc Natl Acad Sci USA 2006; 103: 7065-7070.
107. Altman JD, Moss PA, Goulder PJ et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996. 274: 94-96.
108. J Immunol 2011; 187: 7-9.
109. Scotet E, Peyrat MA, Saulquin X et al. Frequent enrichment for CD8 T cells reactive against common herpes viruses in chronic inflammatory lesions: Towards a reassessment of the physiopathological significance of T cell clonal expansions found in autoimmune inflammatory processes. Eur J Immunol 1999; 29: 973-985.
110. Landais E, Saulquin X, Houssaint E. The human T cell immune response to Epstein-Barr virus. Int J Dev Biol 2005; 49: 285-292.
111. Lee SP, Chan AT, Cheung ST et al. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J Immunol 2000; 165: 573-582.
112. Lin X, Gudgeon NH, Hui EP et al. CD4 and CD8 T cell responses to tumour-Associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients. Cancer Immunol Immunother 2008; 57: 963-975.
113. Moss DJ, Chan SH, Burrows SR et al. Epstein-Barr virus specific T-cell response in nasopharyngeal carcinoma patients. Int J Cancer 1983; 32: 301-305.
114. Steven NM, Annels NE, Kumar A et al. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 1997; 185: 1605-1617.
115. Angelini DF, Serafini B, Piras E et al. Increased CD81 T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog 2013; 9: E1003220.
116. Fogg MH, Wirth LJ, Posner M et al. Decreased EBNA-1-specific CD81 T cells in patients with Epstein-Barr virus-Associated nasopharyngeal carcinoma. Proc Natl Acad Sci USA 2009; 106: 3318-3323.
117. Li J, Zeng XH, Mo HY et al. Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: Implications for tumor immunotherapy. PLoS One 2007; 2: E1122.
118. Martorelli D, Houali K, Caggiari L et al. Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy. Int J Cancer 2008; 123: 1100-1107.
119. Li J, Chen QY, Mo H et al. Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: Implications for adoptive immunotherapy. Int J Biol Sci 2011; 7: 607-617.
120. Brown DM. Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy. Cell Immunol 2010; 262: 89-95.
121. Maini MK, Gudgeon N, Wedderburn LR et al. Clonal expansions in acute EBV infection are detectable in the CD8 and not the CD4 subset and persist with a variable CD45 phenotype. J Immunol 2000; 165: 5729-5737.
122. Munz C, Bickham KL, Subklewe M et al. Human CD4(1) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 2000; 191: 1649-1660.
123. Leen A, Meij P, Redchenko I et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(1) T-helper 1 responses. J Virol 2001; 75: 8649-59.
124. Minarovits J. Epigenotypes of latent herpesvirus genomes. Curr Top Microbiol Immunol 2006; 310: 61-80.
125. Khanna R, Busson P, Burrows SR et al. Molecular characterization of antigenprocessing function in nasopharyngeal carcinoma (NPC): Evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res 1998; 58: 310-314.
126. Levitskaya J, CoramM, Levitsky V et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375: 685-688.
127. Levitskaya J, Sharipo A, Leonchiks A et al. Inhibition of ubiquitin/proteasomedependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 1997; 94: 12616-12621.
128. Zaldumbide A, Ossevoort M, Wiertz EJ et al. In cis inhibition of antigen processing by the latency-Associated nuclear antigen I of Kaposi sarcoma herpes virus. Mol Immunol 2007; 44: 1352-13560.
129. Blake N, Lee S, Redchenko I et al. Human CD81T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 1997; 7: 791-802.
130. Long HM, Taylor GS, Rickinson AB. Immune defence against EBV and EBV-Associated disease. Curr Opin Immunol 2011; 23: 258-264.
131. Blake N, Haigh T, Shaka'a G et al. The importance of exogenous antigen in priming the human CD81 T cell response: Lessons from the EBV nuclear antigen EBNA1. J Immunol 2000; 165: 7078-7087.
132. Voo KS, Fu T, Wang HY et al. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD81 T lymphocytes. J Exp Med 2004; 199: 459-470.
133. Tellam J, Connolly G, Green KJ et al. Endogenous presentation of CD81 T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J ExpMed 2004; 199: 1421-1431.
134. Rowe M, Khanna R, Jacob CA et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: Coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol 1995; 25: 1374-1384.
135. Murray PG, Constandinou CM, Crocker J et al. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr viruspositive Hodgkin's disease. Blood 1998; 92: 2477-2483.
136. Tudor CS, Dawson CW, Eckhardt J et al. c-Myc and EBV-LMP1: Two opposing regulators of the HLA class I antigen presentation machinery in epithelial cells. Br J Cancer 2012; 106: 1980-1988.
137. Smith C, Wakisaka N, Crough T et al. Discerning regulation of cis-And transpresentation of CD81 T-cell epitopes by EBV-encoded oncogene LMP-1 through self-Aggregation. Blood 2009; 113: 6148-6152.
138. Zuo J, Thomas W, van Leeuwen D et al. The DNase of gammaherpesviruses impairs recognition by virus-specificCD81T cells through an additional host shutoff function. J Virol 2008; 82: 2385-2393.
139. Wu CC, Liu MT, Chang YT et al. Epstein-Barr virus DNase (BGLF5) induces genomic instability in human epithelial cells. Nucleic Acids Res 2010; 38: 1932-1949.
140. Li D, Qian L, Chen C et al. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation. J Immunol 2009; 182: 1799-1809.
141. Horst D, van Leeuwen D, Croft NP et al. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. J Immunol 2009; 182: 2313-2324.
142. Croft NP, Shannon-Lowe C, Bell AI et al. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog 2009; 5: E1000490.
143. Yao M, Ohshima K, Suzumiya J et al. Interleukin-10 expression and cytotoxic-T-cell response in Epstein-Barr-virus-Associated nasopharyngeal carcinoma. Int J Cancer 1997; 72: 398-402.
144. Vockerodt M, Haier B, Buttgereit P et al. The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway. Virology 2001; 280: 183-198.
145. Kitagawa N, Goto M, Kurozumi K et al. Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction.EMBOJ 2000; 19: 6742-50.
146. You RI, Chang YC, Chen PM et al. Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3). Blood 2008; 111: 1480-1488.
147. Chang YC, Chen TC, Lee CT et al. Epigenetic control of MHC class II expression in tumor-Associated macrophages by decoy receptor 3. Blood 2008; 111: 5054-5063.
148. Ho CH, Chen CL, Li WY et al. Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion. Carcinogenesis 2009; 30: 1443-1451.
149. Shimakage M, Sakamoto H. Macrophage involvement in Epstein-Barr virus-related tumors. Exp Ther Med 2010; 1: 285-291.
150. Fang W, Zhang J, Hong S et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget 2014; 5: 12189-12202.
151. Gondek DC, Lu LF, Quezada SA et al. Cutting edge: Contact-mediated suppression by CD41CD251 regulatory cells involves a granzyme B-dependent, perforinindependent mechanism. J Immunol 2005; 174: 1783-1786.
152. Chen ML, Pittet MJ, Gorelik L et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA 2005; 102: 419-424.
153. Cao X, Cai SF, Fehniger TA et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007; 27: 635-646.
154. Lau KM, Cheng SH, Lo KW et al. Increase in circulating Foxp31CD41CD25(high) regulatory T cells in nasopharyngeal carcinoma patients. Br J Cancer 2007; 96: 617-622.
155. Marshall NA, Vickers MA, Barker RN. Regulatory T cells secreting IL-10 dominate the immune response to EBV latentmembrane protein 1. J Immunol 2003; 170: 6183-6189.
156. Dukers DF, Meij P, Vervoort MB et al. Direct immunosuppressive effects of EBVencoded latent membrane protein 1. J Immunol 2000; 165: 663-670.
157. Fogg M, Murphy JR, Lorch J et al. Therapeutic targeting of regulatory T cells enhances tumor-specific CD81 T cell responses in Epstein-Barr virus associated nasopharyngeal carcinoma. Virology 2013; 441: 107-113.
158. Fries KL, Miller WE, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J Virol 1996; 70: 8653-8659.
159. Liu MY, Shih YY, Li LY et al. Expression of the Epstein-Barr virus BHRF1 gene, a homologue of Bcl-2, in nasopharyngeal carcinoma tissue. J Med Virol 2000; 61: 241-250.
160. Lo AK, Lo KW, Tsao SW et al. Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia 2006; 8: 173-180.
161. Tang YL, Lu JH, Cao L et al. Genetic variations of EBV-LMP1 from nasopharyngeal carcinoma biopsies: Potential loss of T cell epitopes. Braz J Med Biol Res 2008; 41: 110-116.
162. Horst D, Burrows SR, Gatherer D et al. Epstein-Barr virus isolates retain their capacity to evade T cell immunity through BNLF2a despite extensive sequence variation. J Virol 2012; 86: 572-577.
163. Tsai MH, Raykova A, KlinkeO et al. Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas. Cell Rep 2013; 5: 458-470.
164. Lin CL, Lo WF, Lee TH et al. Immunization with Epstein-Barr Virus (EBV) peptidepulsed dendritic cells induces functional CD81 T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002; 62: 6952-6958.
165. Comoli P, Pedrazzoli P, Maccario R et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-Targeted cytotoxic T lymphocytes. J Clin Oncol 2005; 23: 8942-8949.
166. Straathof KC, Bollard CM, Popat U et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005; 105: 1898-1904.
167. Louis CU, Straathof K, Bollard CM et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 2010; 33: 983-990.
168. Lutzky VP, Corban M, Heslop L et al. Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine. J Virol 2010; 84: 407-417.
169. Taylor GS, Jia H, Harrington K et al. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: A phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res 2014; 20: 5009-5022.
170. Hui EP, Taylor GS, Jia H et al. Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res 2013; 73: 1676-1688.
171. Smith C, Tsang J, Beagley L et al. Effective treatment of metastatic forms of Epstein-Barr virus-Associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 2012; 72: 1116-1125.
172. Wu NC, De La Cruz J, Al-Mawsawi LQ et al. HIV-1 quasispecies delineation by tag linkage deep sequencing. PLoS One 2014; 9: E97505.